Tumor Antigen LRRC15 Impedes Adenoviral Infection: Implications for Virus-Based Cancer Therapy

O'Prey, J., Wilkinson, S. and Ryan, K.M. (2008) Tumor Antigen LRRC15 Impedes Adenoviral Infection: Implications for Virus-Based Cancer Therapy. Journal of Virology, 82(12), pp. 5933-5939. (doi: 10.1128/JVI.02273-07)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1128/JVI.02273-07


Adenoviruses for gene or oncolytic therapy are under development. Notable among these strategies is adenoviral delivery of the tumor suppressor p53. Since all therapeutics have limitations in certain settings, we have undertaken retroviral suppressor screens to identify genes conferring resistance to adenovirus-delivered p53. These studies identified the tumor antigen LRRC15, which is frequently over-expressed in multiple tumor types, as a repressor of cell death due to adenoviral p53. LRRC15, however, does not impede p53 function per se but impedes adenoviral infection. Specifically, LRRC15 causes redistribution of the coxsackievirus-adenovirus receptor away from the cell surface. This effect is manifested in less adenoviral binding to the surfaces of LRRC15-expressing cells. This discovery, therefore, not only is important for understanding adenoviral biology but also has potentially important implications for adenovirus-based anticancer therapeutics.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Ryan, Professor Kevin and Wilkinson, Dr Simon and O'Prey, Mr James
Authors: O'Prey, J., Wilkinson, S., and Ryan, K.M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Journal of Virology

University Staff: Request a correction | Enlighten Editors: Update this record